Monopar Therapeutics Inc.
MNPR
$80.13
-$2.43-2.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.61% | 27.60% | -2.33% | -8.81% | -1.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.07% | 119.94% | 83.01% | -28.79% | -26.35% |
| Operating Income | -155.07% | -119.94% | -83.01% | 28.79% | 26.35% |
| Income Before Tax | -142.96% | -117.78% | -85.50% | 31.73% | 28.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -142.96% | -117.78% | -85.50% | 31.73% | 28.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.96% | -117.78% | -85.50% | 31.73% | 28.26% |
| EBIT | -155.07% | -119.94% | -83.01% | 28.79% | 26.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -43.66% | -31.00% | -17.72% | 44.09% | 39.31% |
| Normalized Basic EPS | -43.67% | -30.99% | -17.73% | 44.08% | 39.31% |
| EPS Diluted | -43.66% | -31.00% | -17.72% | 44.21% | 39.58% |
| Normalized Diluted EPS | -43.67% | -30.99% | -17.73% | 44.08% | 39.31% |
| Average Basic Shares Outstanding | 79.98% | 62.60% | 36.76% | 22.82% | 19.35% |
| Average Diluted Shares Outstanding | 79.98% | 62.60% | 36.76% | 22.82% | 19.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |